Emoticon Optics (Emoxi-optic)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceMethyl ethylpyridinolMethyl ethylpyridinol
Similar drugsTo uncover
  • Cardiocipine
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Cardiocipine
    solution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Methyl ethylpyridinol
    solution for injections 
    ATOLL, LLC     Russia
  • Methyl ethylpyridinol
    solution for injections 
    ELLARA, LTD.     Russia
  • Methyl ethylpyridinol
    solution for injections 
    Company DEKO, LLC     Russia
  • Methyl ethylpyridinol-Eskom
    solution for injections 
    ESKOM NPK, OAO     Russia
  • Emoticon Optics
    drops d / eye 
    SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products     Russia
  • Emoxibel
    solution d / infusion 
       
  • Emoxibel
    solution for injections 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Emoxibel
    drops d / eye 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Emoxibel
    solution w / m in / in 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Emoxipine®
    drops d / eye 
    MOSCOW ENDOCRINE FACTORY, FSUE     Russia
  • Emoxipine
    solution w / m in / in 
    MOSCOW ENDOCRINE FACTORY, FSUE     Russia
  • Emoxipine
    drops d / eye 
    FARMENT FIRM, LLC     Russia
  • Emoxipine
    solution for injections 
    MOSCOW ENDOCRINE FACTORY, FSUE     Russia
  • Emoxipine-AKOS
    drops d / eye 
    SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products     Russia
  • Emoxipine-Acti
    solution d / infusion 
    Aktifarm, OOO     Russia
    • Dosage form: & nbspEye drops.
    Composition:1 ml of the solution contains:
    Active substance: methyl ethylpyridinol hydrochloride 10 mg.
    Excipients: sodium sulfite (sodium sulfite anhydrous), sodium benzoate, potassium dihydrogen phosphate (potassium phosphate monosubstituted), sodium hydrogen phosphate dodecahydrate (sodium phosphate disubstituted 12-water), methylcellulose, water for injection.
    Description:Colorless or slightly colored slightly opalescent liquid.
    Pharmacotherapeutic group:Antioxidant.
    ATX: & nbsp

    S.01.X.A   Other drugs for the treatment of eye diseases

    Pharmacodynamics:Antioxidant (a drug that prevents the lipid peroxidation of cell membrane lipids), which possesses angioprotective (vascular stability), antiaggregatory (preventing platelet adhesion) and antihypoxic (increasing tissue resistance to oxygen deficiency) activity.
    Reduces the permeability of capillaries and strengthens the vascular wall (angioprotector). Reduces blood viscosity and platelet aggregation (antiaggregant). The inhibitor of free-radical processes, has a membrane-stabilizing action.
    Has retinoprotective properties, protects the retina and other eye tissues from the damaging effect of high-intensity light. Promotes resorption of intraocular hemorrhages, reduces blood clotting, improves microcirculation of the eye. Stimulates reparative processes in the cornea (including in the early postoperative and post-natal period).
    Pharmacokinetics:Quickly penetrates into the organs and tissues, where it is deposited and metabolized.
    In the tissues of the eye, the concentration is higher than in the blood.
    Five metabolites, dealkylated and conjugated, were detected. products of transformation. Metabolites are excreted by the kidneys. In significant quantities, 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in the liver.
    Indications:It is used in adults with the following diseases and conditions:
    - hemorrhages in the anterior chamber of the eye (treatment);
    - hemorrhages in the sclera in the elderly (treatment and prevention);
    - inflammation and burns of the cornea (treatment and prevention);
    - complications with myopia (treatment);
    - protection of the cornea (when wearing contact lenses).
    Contraindications:Hypersensitivity. Pregnancy.Lactation (breastfeeding), children under 18 years.
    Dosing and Administration:The drug is instilled in the conjunctival sac 1-2 drops 2-3 times a day. The course of treatment is 3-30 days. If necessary and well tolerated, the course of treatment can be continued up to 6 months and can be repeated 2-3 times a year.
    Side effects:Burning sensation, itching, short-term conjunctival hyperemia, rarely - local allergic reactions.
    Overdose:Not installed..
    Interaction:The drug should not be mixed with other drugs.
    Special instructions:If it is necessary to simultaneously apply other eye drops, the drug is digested last, after complete absorption of the previous drops (not less than 10-15 minutes).
    Form release / dosage:Eye drops 1%.
    Packaging:To 5 or 10 ml in bottles of colorless glass.
    To 5 ml or 10 ml in bottles with a nozzle-dispenser and a cap screwed from plastic.
    1 bottle of plastic with instruction for use is placed in a pack of cardboard.
    1 glass bottle with instructions for use and a lid-dropper placed in a pack of cardboard, or without a cap-dropper.
    Storage conditions:List B.In the dark place at a temperature of no higher than 25 ° C.
    Keep out of the reach of children.
    Shelf life:2 years. After opening the vial, use within 1 month.
    Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:P N002264 / 01
    Date of registration:25.04.2008 / 27.08.2009
    Expiration Date:Unlimited
    The owner of the registration certificate:SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products Russia
    Manufacturer: & nbsp
    Information update date: & nbsp2016-08-27
    Illustrated instructions
      Instructions
      Up